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Abstract
Background Recommended follow-up intervals after endo-
scopic removal of hyperplastic polyps (HP) and sessile serrat-
ed adenomas (SSA) differ because of assumed differences in
biological behaviour. However, histopathologic differentia-
tion is difficult, with higher SSA rates reported from specialist
GI histopathologists.
Objective The objective of this study was to clarify the rele-
vance of histologic reassessment of HP.
Design and setting From a prospective screening colonosco-
py study relevant serrated lesions (excluding distal small HP
≤5 mm) diagnosed by private practice pathologists were
reassessed by four specialized GI pathologists
Patients One thousand sixty-nine screening colonoscopies
were performed in patients.
Main outcome measurements In terms of main outcome mea-
surements, there is a likelihood of changes of the HP diagnosis
on reassessment, as well as interrater variability.
Results SSA were initially diagnosed in 7 cases (0.7 %) and
relevant HP in 83 (7.8 %; 101 lesions). Of the latter, the
chance of a change in diagnosis from HP to SSA by any of
the four specialist histopathologists was higher for larger
(>5 mm) and right-sided lesions (19.1 vs 1.3 %, OR 18.4,
p=0.04) including a higher likelihood to change recommend-
ed follow-up intervals (32.1 vs 3.3 %, p<0.01). However,
follow-up intervals were determined by concomitant adeno-
mas in 41 %. Interrater variability was also higher for these
lesions (p = 0.04), with an overall kappa value of 0.48.
However, this issue related to only 1.2 % of the 1069 study
cases.
Limitation The limitations this study are the limited case num-
ber as well as limited retrospective assessment.
Conclusions Right-sided HP >5 mm had a higher chance of
change in diagnosis to SSA; therefore, they should probably
be treated like adenomas and be removed. However, reliable
data for recommendations on follow-up intervals of HP or
SSAwill require follow-up studies.
Keywords Histopathological second opinion . Serrated
lesions . Hyperplastic polyps . Screening colonoscopy
Introduction
Colorectal polyps are increasingly detected during colonosco-
py both due to more colonoscopies being performed within
various screening programmes and due to increasing aware-
ness of endoscopists; recently, it has been shown more adeno-
mas are found during screening colonoscopy within the
German screening programme, just to name one example
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[1]. Therefore, the correct recognition, assessment and classi-
fication of colorectal polyps are of paramount importance for
further management. Of these polyps, serrated polyps/lesions
or adenomas have recently attracted much attention [2].
Serrated colonic lesions consist of several subgroups, the
most important of which are hyperplastic polyps (HP) and
sessile serrated adenomas (SSA) in terms of frequency. The
biological behaviour of those two types is considered to be
different: SSA are widely recognized as precursor lesions of
serrated pathway colorectal carcinoma [2, 3], while HP are
still considered to have no malignant potential. The preva-
lence of SSA remains unclear, varying between 2.8 % (stan-
dard care) and 9 % (single-expert endoscopy and pathology
reports) in patients undergoing screening and/or diagnostic
colonoscopy [4–7]. Similarly, although there are two different
variants of the pathway from serrated adenomas to colorectal
carcinoma with regards to cancer aggressiveness [8], the rele-
vance in clinical practice especially with regards to screening
colonoscopy and associated adenoma findings is not yet clear.
A detection rate of 5 % has been suggested for proximal
serrated lesions for average-risk men and women undergoing
screening colonoscopy [9] including both HP and SSA. With
regards to their relative distribution within the group of serrat-
ed lesions, the rise of SSA detection rate over time [10] could
be at least partially due to a shift in diagnosis from hyperplas-
tic polyps on histopathological review [11, 12]. The distinc-
tion between SSA and HP, however, may be difficult, and
previous studies have also reported poor to fair interobserver
agreement rates for histopathological diagnosis of SSAversus
HP, with kappa values ranging from 0.16 to 0.38 [11, 13, 14].
For these reasons, diagnostic criteria for SSA have been re-
cently refined by several expert panels and consensus confer-
ences [2, 15], in the hope of arriving at a more uniform and
reproducible histopathological diagnosis.
From a clinical point of view, guideline follow-up intervals
differ for true hyperplastic polyps (if they are the only polyps
found) and for SSA. The recommended follow-up for hyper-
plastic polyps is 10 years, whereas that for SSA, which is
analogous with those of conventional adenomas, varies be-
tween 3 and 5–10 years, depending on size, number and his-
tology [16, 17]. Because of the uncertainties in histological
diagnosis mentioned above, the current study analyses the
value of a second opinion for smaller serrated polyps
(≤10 mm) removed during screening colonoscopy.
Methods
Case selection and reassessment
All colonic hyperplastic polyps were selected from a previously
published study [18] on the endoscopic differential diagnosis of
colonic polyps, which had been originally interpreted as hyper-
plastic polyps by private practice pathologists. Out of these,
hyperplastic polyps that were distally located (below the splenic
flexure) and were ≤5 mm in size were excluded: This was done
because such small whitish polyps can usually be recognized at
endoscopy as hyperplastic and are almost always histologically
confirmed as such if resected or removed under biopsy.
Furthermore, for these reasons, they are often even left in place
especially if they are diminutive andmultiple. Thus, in summary,
the case selection for this study included all HP on the right side
(oral of the splenic flexure) and HP >5 mm on the left side
(aboral of the splenic flexure).
These selected cases were pseudonymized (only sex and
age were known) and were reassessed by four specialized
gastrointenstinal (GI) pathologists (M.C., D.A., L.B., M.V.)
using the original haematoxylin and eosin (H&E)-stained
slides with serial sections; the diagnostic criteria for SSAs
are shown in Table 1. These histopathologists had specific
interest in colonic pathology and had already published on
the topic and/or were involved in consensus meetings on
polyps and SSA. To mimic a second-opinion procedure, the
four pathologists were not blinded to the original diagnosis by
community pathologists (namely, all diagnosed as HP) of the
lesions they reviewed. That is, the histopathologists involved
in reassessment knew that they reassessed polyps of all sizes
in the right colon and polyps of 5 mm and more in the left
colon which had been originally given the diagnosis of a hy-
perplastic polyp in the primary histopathological workup; this
closely mimics a second-opinion process. In their reassess-
ment, they had to choose between genuine HP, SSA, tradition-
al serrated adenoma (TSA) and conventional adenoma. As
required by the German reimbursement system, at least eight
serial sections have to be available per polyp; all histopathol-
ogists received these serial sections for reanalysis.
With regards to removal technique, all polyps of more than
5 mm diameter had been removed by snare, and smaller
polyps by either snare of biopsy forceps using multiple bites.
Table 1 Microscopic criteria for diagnosis of SSA according to the
German Society of Pathology [15]
• Hyperserration, serration in the lower third of the crypts with and
without branching of the crypts
• T- or L-shaped crypts above the muscularis mucosae
• Inverted crypts (pseudoinvasion) below the muscularis mucosae
• Columnar dilatation in the lower third of the crypts (with and without
presence of mucus)
• Shifting of proliferation zone to the middle third of the crypts
• Vesicular nuclei with nucleoli
• Mature goblet cells at the base of the crypts
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Outcomes
Main outcome There is likelihood of a change in diagnosis
(from HP to SSA or adenoma) on a lesion basis.
Secondary outcomes & There is a likelihood of a shortening
of recommended follow-up inter-
vals on a per-patient basis, namely,
shortening from 10 years (based on
a diagnosis of HP only) to either 3
or 5–10 years based on the presence
of adenomas. For this analysis,
SSA were treated like adenomas
with respect to follow-up recom-
mendations [16, 17], although this
practice might not be regarded as
finally established. Follow-up rec-
ommendations were based on re-
cent guidelines which can be sum-
marized for this analysis as follows:
5–10 years are recommended for
one to two adenomas <10 mm in
size, while 3 years are recommend-
ed for three to ten adenomas even if
smaller (the other criteria relate to
larger sizes or more advanced his-
tology than that found in our study
on small polyps) [16, 17]. To cate-
gorize follow-up intervals, 3 and 5–
10-year recommendations were
taken together as Bshortening in
follow-up intervals^ due to limited
sample size of HPs selected for the
study.
& There is an interrater variability between the four special-
ized GI pathologists in the diagnosis of HP versus adeno-
ma/SSA.
Statistical analysis
Change in diagnosis and subsequent change in follow-up
recommendation For these analyses, change of diagnosis
of polyps was considered on a lesion basis, while change in
follow-up recommendation was analysed on a per-patient
basis (for patients without concomitant adenomas). We
used the following assumptions: A Bchange in diagnosis/
follow-up^ would occur if any histopathological second
opinion led to the diagnosis Bnot HP but adenoma and/or
SSA^. As predictors for Bchange in diagnosis/follow-up
yes/no^, we used the following variables: size, location
(left/right), interaction between size and location, age, sex
and occurrence of one or more lesion. Additionally, we
employed the same model but using size as a categorical
variable with the cutoff of 5 mm (≤5 vs >5 mm).
We estimated a random intercept model with change in
follow up yes/no as outcome and crossed random effects of
pathologist and patient. The benefit of this modelling is
that both pathologist and patient were treated as random
selections. For both, the median odds ratios (MORs) were
applied to quantify the variation between clusters by com-
paring two different patients (or two pathologists) from
two randomly chosen, different clusters, as outlined in de-
tail elsewhere [19]. Principally, as described in that paper,
when two persons with the same covariates, chosen ran-
domly from two different clusters, are considered, BThe
MOR is the MOR between the person of higher propensity
and the person of lower propensity. … The measure is
always greater than or equal to 1. If the MOR is 1, there
is no variation between clusters (no second-level varia-
tion). If there is considerable between-cluster variation,
the MOR will be large. The measure is directly comparable
with fixed-effects odds ratios^.
Analogous modelling was used for estimating the likeli-
hood of a change in diagnosis on a lesion basis. The random
intercept was changed from patient to lesion clusters, and an
additional predictor, namely, coexistence of adenoma(s) in the
same patient, was included in the model. Using the likelihood
ratio test, all insignificant interactions and variables were ex-
cluded from the models (backward elimination).
Interobserver agreement We fitted an ordinal regression
with the following agreement outcomes: 0 = no assessment
possible; 1 = two out of four pathologists agreed;
2 = pairwise agreement; 3 = three out of four pathologists
agreed; and 6 = total agreement. As predictors for agree-
ment, we used the following variables: size, location
(left/right), interaction between size and location, age,
sex, occurrence of one or more lesion(s) and coexistence
of adenoma(s) in the same patient.
Nominal p values are reported without correction for mul-
tiplicity, and p values <0.05, two-sided, were considered sig-
nificant. All analyses were conducted using Stata 13.1
(StataCorp, College Station, Texas, USA.
Results
Patients and polyps
Patient numbers for polyps of different histology and the
case selection for this study are shown in Fig. 1. The ade-
noma detection rate, that is, the percentage of patients with
at least one adenoma detected, was 28.2 %, and 170
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patients were found to have serrated lesions, i.e., HP and
SSA (170/1069; 15.9 %). Amongst these 170 patients,
there were 101 hyperplastic polyps that met the inclusion
criteria for this study, found in 83 patients (41 women, 42
men; mean age 62 years, range 52–84 years). In addition,
six further serrated lesions had been primarily diagnosed as
SSA by community pathologists but were not included in
the reassessment.
The mean polyp size was 5 mm (range 1–10 mm); 34 HP
were left-sided with mean size of 6 mm (size range 5–10 mm,
see inclusion criteria), and 67 were right-sided with mean size
4 mm. No HP larger than 10 mm was found during the study
in the 1069 patients. Biopsy forceps had been used to remove
51 lesions and snare polypectomy for 50 lesions.
HP polyp reassessment (second opinion, 101 lesions in 83
patients)
Figures 1 and 2 show the results of the reassessment of the 101
hyperplastic polyps by four specialized GI pathologists.
Likelihood of a change in diagnosis The likelihood for a
change in diagnosis from HP to SSA by any of the four
specialized histopathologists was higher for right-sided,
§  5 SSA in 4 patients
#  including one change in follow up from 5 to 3 years 
due to increased number of adenomas.
Patients with 
adenomas 
only
N=234
All patients N=1069
Patients 
with 
adenomas 
and SSA
N=2
Patients with 
hyperplastic 
polyps only
N=100
Patients with 
hyperplastic 
polyps and 
SSA
N=1*
Patients 
with SSA§
only
N=4
54 hyperplastic 
polyps
from 
49 patients (no
concomitant 
adenomas)
47 hyperplastic 
polyps
from
34 patients
(concomitant 
adenomas)
101 hyperplastic polyps
of 83 patients reassessed**
Patients with 
adenomas and 
hyperplastic 
polyps
Follow-up 
determined by 
adenomas
N=34
Patients with 
hyperplastic 
polyps only
Follow-up would 
be 10 years
N=49
Patients with 
hyperplastic 
polyps and 
SSA
Follow-up 
determined by 
SSA
N=1
Reassessment No change in 
follow-up**
No change in 
follow-up
Patients with 
adenomas + 
hyperplastic
polyps
N=64
Selection of hyperplastic polyps 
excluding small (≤5 mm) distal lesions
Patients with 
adenomas and/ or 
SSA
Follow-up 
determined by 
adenomas
N=240
No change in 
follow-up
>5 mm and right-sided 
lesions
N=13 patients
Shorter follow-up 
(3–5 years)
≤5 mm, all left-sided 
lesions
N=36 patients
No change in follow-up
Fig. 1 Flowchart showing study
patients, group distribution with
regard to polyp type, result of
histopathological reassessment of
polyps and change in follow-up
recommendations (see text). SSA
sessile serrated adenomas.
*Excluded from reassessment
since HP size was < 5 mm. **See
Fig. 2 for results of reassessment
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larger (>5 mm) HP lesions, at 19.1 versus 1.3 %, with an
OR of 18.4 (95 % CI 1.1–294, p= 0.04). None of the other
analysed factors showed any effect. Endoscopic and histo-
logic examples are shown in Figs. 3 and 4.
Interobserver agreement (Table 2)
Overall kappa for the confirmation of HP was 0.448 (95 %
CI 0.28–0.60; p<0.001). Using ordinal regression for the de-
gree of agreement defined above, after the backward elimina-
tion, only the interaction between size and location and the
patient age showed a significant influence on interobserver
agreement. The proportional odds assumption was not
violated.
With increasing patient age, the probability of agreement
decreased (OR 0.92, 95 % CI 0.86–0.99; p=0.024). For left-
sided lesions, polyp size had no effect on agreement, with an
OR of 1.01 (95 % CI 0.58–1.76; p=0.967). Over all observed
sizes (5–10mm) for left-sided lesions, the adjusted probability
of total agreement was 72.5 % (95 % CI 55.4–89.7 %). For
right-sided lesions, the probability of agreement decreased by
size, with an OR of 0.55 (95 % CI 0.42–0.73; p<0.001). This
different effect of size by location was significant (p=0.039).
In summary, agreement was worst for larger (>5 mm) right-
sided lesions (OR 0.22, 95 % CI 0.07–0.65, p=0.006) as
compared to smaller and left-sided polyps. This is shown in
detail in Fig. 5.
101 hyperplastic polyps in 83 patients reassessed
47 hyperplastic polyps in 34 patients 
with concomitant adenomas
54 hyperplastic polyps in 49 patients without 
concomitant adenomas
Not assessable 
for technical 
reasons
n=1
30 hyperplastic 
polyps confirmed 
in 21 patients
61 hyperplastic polyps (60.3%)
confirmed by consensus 
in 51 patients* (61.4%)
4 polyps in 
3 patients:
Change of diagnosis 
to adenoma
6 polyps in 5 patients*
changed diagnosis by consensus
to either adenoma (4) or SSA (2)
No consensus:
12 polyps in 
12 patients
No consensus
33 polyps (32.7%) 
in 33 patients* (39.8%)* #
31 hyperplastic 
polyps confirmed 
in 30 patients
2 polyps in 
2 patients:
Change of diagnosis 
to SSA
No consensus:
21 polyps in 
21 patients
*The total number of polyps is 101 (61 + 6 + 33+1), but the total number of patients is higher (51 + 5 + 33 = 89 instead of 83) since there were 6 patients with at least two hyperplastic 
polyps who appear in two different subgroups with regard to consensus.
Fig. 3 Ten millimeter-right-sided flat lesion, with indeterminate
assessment by the four GI histopathologists (two hyperplastic/two
sessile serrated adenoma). a Endoscopy, very flat lesion with glossy
appearance from some distance, considered typical for sessile serrated
adenoma. b Histology, a hyperplastic polyp with serration, no complex
architecture, nomicro-herniation, no basal goblet cells and no T-shaped or
L-shaped glands
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Fig. 2 Flowchart showing reassessment results (see text). *The total
number of polyps is 101 (61 + 6 + 33 + 1), but the total number of
patients is higher (51 + 5 + 33 = 89 instead of 83) since there were six
patients with at least two hyperplastic polyps who appear in two
different subgroups with regard to consensus
Change in follow-up recommendations
In patient group, follow-up would change to shorter inter-
vals with a change in diagnosis to SSA (or adenoma) after
reassessment of HP. These possible changes in follow-up
recommendations based on a change in HP diagnosis fol-
lowing histopathological reassessment are shown in Fig. 1.
Overall, 34/83 patients (41 %) had concomitant adenomas/
SSA; these determined the follow-up interval, and these
patients are not considered in the following analyses. The
subgroup of HP patients without concomitant adenomas/
SSA comprised 49 patients (28 women, 21 men; mean age
63 years, range 52–84) with 54 lesions. Mean polyp size
was 5.22 mm (range 2–10 mm); 17 lesions were in the left
colon (3 lesions >5 mm, 17.7 %), and 37 were right-sided
(14 lesions >5 mm, 37.8 %). In only one case, the addi-
tional diagnosis of a small adenoma from the original di-
agnosis of HP would have shortened follow-up intervals
due to the increase in numbers of adenomas from two to
Fig. 4 Five millimeter-left sided
sharply demarcated polyp (reas-
sessment 3:1 for sessile serrated
adenoma vs hyperplastic polyp).
a Endoscopy (white light, left,
and i-scan mode, right) shows a
sessile lesion with villous features
suggesting adenoma.
b Histology shows a polyp with
serration, tangential cut mimick-
ing micro-herniation, but no
complex architecture, no micro-
herniation and some basal goblet
cells, T- or L-shaped glands seem
to be present but, due to tangential
cut, hard to assess. As far as from
this tangential cut, it could be
concluded that the lesion is
representing a hyperplastic polyp
Table 2 Kappa values for four raters in relation to the histological
diagnosis
Outcome Kappa N p Value
Not assessable 1 1 <0.001
HP or less 0.4696 61 <0.001
Adenoma 0.8493 4 <0.001
SSA 0.3123 2 <0.001
Combined 0.4838 <0.001
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three; the other patients had less than three adenomas even
with diagnostic changes after reassessment.
Overall, also in this subgroup, the likelihood of reduction
of follow-up interval was also significantly increased for pa-
tients with larger (>5 mm) right-sided lesions (32.1 %, 95 %
CI 0–71.2% vs 3.3%, 95%CI 0–9.2%; p<0.01), resulting in
an almost 14-fold higher chance as compared with patients
with all other lesions (OR = 13.8, 95 % CI 2.3–84.7;
p=0.004). With regards to the influence of different patholo-
gists and possible differences between patients, the MOR was
3.2 (95 % CI 1.6–15.8) for pathologists and 6.2 (95 % CI 2.8–
25.2) for patients (see BMethods^ section). In relation to the
entire patient group (n=1069), changes in follow-up recom-
mendation arising from histopathological reassessment of HP
would occur in only about 1 % of cases overall (see Fig. 1).
Discussion
Colorectal adenomas are known precursor lesions of colorec-
tal carcinoma, and on the detection and removal of these ad-
enomas rests the preventive effect of colorectal cancer screen-
ing including stool tests and colonoscopy. Up to now, these
polyps were mainly differentiated into hyperplastic polyps
and adenomas. In recent years, sessile and TSAs have been
identified as separate lesions which may be precursor lesion in
the so-called serrated and alternate pathways of colorectal car-
cinogenesis [3, 20]. Therefore, correct diagnosis and differen-
tial diagnosis of serrated lesions (hyperplastic polyps, sessile
and TSAs) is very important for further management includ-
ing follow-up.
Among colonic serrated lesions, SSA have aroused great
interest in recent years, mainly because of their different path-
way to colorectal cancer [21, 22]. They could also be missed
more frequently, since they are mostly flat lesions and located
in the right colon. Histological criteria have been developed
on the basis of morphological changes andmarker expressions
[2, 15]. The malignant potential of SSA has been regarded as
substantial by some groups [23], but no consensus exists
about both their occurrence and overall cancer risk in a broad
community setting. BTruly^ hyperplastic polyps constitute
separate subgroups in the WHO classification of serrated le-
sions in the colorectum [24]; in the past, they have been con-
sidered to harbour no malignant potential [25]. This, however,
seems to be based onmorphological assessment rather than on
large and meticulous follow-up studies; furthermore, recent
data suggest that mutational changes may already have oc-
curred at the hyperplastic polyp stage [26].
With regard to the histopathological diagnosis of serrated
lesions, it has been shown previously that the diagnosis of
these polyps made by community histopathologists is often
not confirmed in a second-opinion procedure by specialized
GI pathologists—findings confirmed by our study. In earlier
studies on serrated lesions, it has already been stated that
Bthere is great morphologic variability in SPs [serrated polyps]
in the large intestine and what has been considered by some to
be a morphologic continuum between HPs and SSA (e.g., as
part of the Bhyperplastic polyp-serrated adenoma-carcinoma
sequence^) may not truly be a continuum but rather may rep-
resent an inability to separate these lesions based on a super-
ficial evaluation of the morphologic features^ [24]. In 2009,
Douglas Rex’s group showed that in a historical group of 40
hyperplastic polyps diagnosed in 2001, 30–85 % of these
polyps were reinterpreted as SSA by gastrointestinal patholo-
gists in 2007. Already then, interobserver agreement between
specialized GI pathologists was seen to be poor with a very
low kappa value (0.16) [11]. Our kappa value of 0.48 is in the
moderate range, in line with most interobserver results in his-
topathologic and endoscopic assessment studies, especially
when observers from different departments are involved,
Fig. 5 Estimated effect of lesion
location and size on interrater
agreement, according to left-sided
(blue) and right-sided (green)
polyp location
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which muchmore relates to daily reality than experts from one
single center.
The low rate of SSA diagnosed primarily in our study may
reflect a lower rate during screening in daily practice as well as
an underdiagnosis by community pathologists; taken together
with HP, the overall rate of serrated lesions (8.4 %) correlates
well with other papers: A study from Canada in 2012 demon-
strated that in a provincial pathology database including 4096
colon polyps, 635 were reported as hyperplastic, most of them
(81.3 %) being left-sided. Of the 119 right-sided HP, 114 were
re-analysed by two specialized GI pathologists using a mutual
consensus process, alongside 90 randomly selected left-sided
HP. In this study, 17% of right-sided polyps and 20% of those
>5 mm were reclassified as SSA [12]. In a similar study from
Australia, 6340 colorectal polyps diagnosed by one histopa-
thologist were reviewedwith regards to the occurrence of SSA
which formed 12.1 % of this group (n=741); 80 % were
located in the proximal colon. Interobserver concordance
was analysed in a small subset of cases (n=90) and was found
to be good (kappa 0.66). Of the SSA subtypes, concordance
was 100 % for SSA and 90 % for pSSA, defined as below the
WHO definition threshold for SSA-type crypt number [27]. In
contrast, two further studies on interobserver agreement found
rather disappointing results [13, 14].
Our study was different from previous ones as we focused
on serrated polyps up to 10 mm (none was larger than 10 mm
in our patient group) and excluded obvious and Beasy^ HP
cases, namely, diminutive polyps (<5 mm) in the distal
colorectum. Thus, the subgroup represents the most difficult
cases for histopathological assessment; on the other hand,
these smaller lesions are those for which the histopathological
classification is discussed most. In our study with an overall
adenoma detection rate of 28 %, the rate of sessile serrated
lesions in the entire patient group was 15.9 % and the rate of
proximal serrated lesions 5.4 %. Our private practice histopa-
thologists may not be comparable with community patholo-
gists included in other studies since they represent variable
levels of experience and specialization, but none of them with
specific and scientific interest in colonic serrated adenomas.
We also attempted to bring together the consequences of a
second-opinion process with the issue of interobserver agree-
ment: Although histopathology re-review of polyps diagnosed
primarily as hyperplastic revealed different diagnoses from
HP in 40 % of cases, interobserver agreement among the GI
pathology specialists was moderate. Even more importantly,
however, proximal and larger HP lesions had a high risk of a
change in diagnosis but also had the highest interrater vari-
ability among GI specialized histopathologists. These results
reflect the different weighting of diagnostic criteria for serrat-
ed lesions by the pathological community. Thus, a second
opinion process is not worthwile at the present state of knowl-
edge in daily practice given the uncertainties in endoscopic
and histopathologic diagnosis and the lack of knowledge of
long-term behaviour of serrated lesions. In the meantime, and
in the light of our results and those of others, we would rec-
ommend to remove these lesions as if they were adenomas
and not remove them under biopsy.
New and cost-effective histopathological markers are
therefore in great demand, at least theoretically. It is likely that
using markers such as BRAF, c-MYC oncogene and SIRT1
protein may be helpful in determining the risk status of serrat-
ed lesions [23] but may significantly increase costs of histo-
pathological analysis. As mentioned, it is still unclear, wheth-
er, alternatively, sophisticated endoscopic methods may pro-
vide similar results in the future. Studies on follow-up after
removal of sessile lesions are required to see whether there are
any differences between them beyond the well known param-
eters of patient age and sex and polyp size, form and location.
For the time being, it could be considered whether right-
sided HP lesions >5 mm should receive a follow-up regimen
similar to that of SSA and adenomas, even if the primary
histopathologic diagnosis was hyperplastic polyp. We could
show that histological reassessment within a second-opinion
process does not make sense, since there was both a high
likelihood for a change in diagnosis and at the same time a
high interrater variability. Finally, this would concern only a
small minority of patients (1 % overall and 6 % of the 83
patients with HP only) as also shown in our study, since about
half of HP patients have concomitant adenomas which almost
always determine follow-up intervals.
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